Price
$3.28
Increased by +2.5%
Dollar Volume (20D)
117.47 K
ADR%
10.57
Earnings Report Date (estimate)
Mar 28, 24
Shares Float
24.13 M
Shares Outstanding
43.83 M
Shares Short
21.94 K
Market Cap.
142.02 M
Beta
0.53
Price / Earnings
N/A
20D Range
3.02 3.8
50D Range
1.44 4.38
200D Range
1.1 4.38
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 29, 23 -0.42
Decreased by -16.67%
-0.38
Decreased by -10.53%
Aug 31, 23 -1.48
Decreased by -92.21%
-0.38
Decreased by -289.47%
May 31, 23 -0.38
Increased by +28.3%
-0.38
Mar 28, 23 -1.55
Decreased by -229.79%
-0.4
Decreased by -287.5%
Nov 30, 22 -0.36
Decreased by -33.33%
-0.36
Aug 30, 22 -0.77
Decreased by -28.33%
-0.65
Decreased by -18.46%
Jun 1, 22 -0.53
Increased by +13.11%
-0.53
Mar 31, 22 -0.47
Increased by +69.68%
-0.67
Increased by +29.85%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Jun 30, 23 N/A
Decreased by N/A%
N/A
Decreased by N/A%
- -
Mar 31, 23 8.42 M
Decreased by -9.48%
-51.15 M
Decreased by -19.92%
Decreased by -607.32%
Decreased by -32.48%
Dec 31, 22 N/A
Decreased by N/A%
N/A
Decreased by N/A%
- -
Sep 30, 22 N/A
Decreased by N/A%
N/A
Decreased by N/A%
- -
Jun 30, 22 N/A
Decreased by N/A%
N/A
Decreased by N/A%
- -
Mar 31, 22 9.3 M
Increased by +5.36 K%
-42.65 M
Decreased by -423.18%
Decreased by -458.43%
Decreased by -105.92%
Dec 31, 21 N/A
Decreased by -100%
N/A
Decreased by -100%
- -
Sep 30, 21 N/A
Decreased by N/A%
N/A
Increased by +100%
- -
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Adagene Inc., a clinical stage immunotherapy company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.